AR-882 is under clinical development by Arthrosi Therapeutics and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase I drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AR-882’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AR-882 overview
AR-882 is under development for the treatment of gout, hyperuricemia, chronic kidney disease (CKD). It is formulated as suspension and administered through oral route. It acts by targeting uric acid transporter 1 (URAT1).
See Also:
Arthrosi Therapeutics overview
Arthrosi Therapeutics (Arthrosi) is the biotech company that carries out drug development and discovery. It focused on the development of therapy for gout and chronic kidney disease. Arthrosi’s product Portfolio includes gout, refractory tophaceous gout, chronic kidney disease and non-small cell lung cancer. The proprietary molecule, AR882, designed to lower uric acid, diminish tophi, and reduce gout flares – without renal safety issues. AR882 is a potent uricosuric drug undergoing development for the treatment of gout. It operates in Australia and China. Arthrosi is headquartered in San Diego, California, the US.
For a complete picture of AR-882’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
